These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 23249693)

  • 1. The CXCR4-CXCL12 axis in Ewing sarcoma: promotion of tumor growth rather than metastatic disease.
    Berghuis D; Schilham MW; Santos SJ; Savola S; Knowles HJ; Dirksen U; Schaefer KL; Vakkila J; Hogendoorn PC; Lankester AC
    Clin Sarcoma Res; 2012 Dec; 2(1):24. PubMed ID: 23249693
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The CXCR4 antagonist plerixafor (AMD3100) promotes proliferation of Ewing sarcoma cell lines in vitro and activates receptor tyrosine kinase signaling.
    Berning P; Schaefer C; Clemens D; Korsching E; Dirksen U; Potratz J
    Cell Commun Signal; 2018 May; 16(1):21. PubMed ID: 29776413
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stress-induced CXCR4 promotes migration and invasion of ewing sarcoma.
    Krook MA; Nicholls LA; Scannell CA; Chugh R; Thomas DG; Lawlor ER
    Mol Cancer Res; 2014 Jun; 12(6):953-64. PubMed ID: 24651452
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fluorescent CXCR4 targeting peptide as alternative for antibody staining in Ewing sarcoma.
    Sand LGL; Buckle T; van Leeuwen FWB; Corver WE; Kruisselbrink AB; Jochemsen AG; Hogendoorn PCW; Szuhai K
    BMC Cancer; 2017 May; 17(1):383. PubMed ID: 28549419
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stromal derived factor-1 (SDF-1/CXCL12) and CXCR4 in renal cell carcinoma metastasis.
    Pan J; Mestas J; Burdick MD; Phillips RJ; Thomas GV; Reckamp K; Belperio JA; Strieter RM
    Mol Cancer; 2006 Nov; 5():56. PubMed ID: 17083723
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CXCL14, CXCR7 expression and CXCR4 splice variant ratio associate with survival and metastases in Ewing sarcoma patients.
    Sand LG; Scotlandi K; Berghuis D; Snaar-Jagalska BE; Picci P; Schmidt T; Szuhai K; Hogendoorn PC
    Eur J Cancer; 2015 Nov; 51(17):2624-33. PubMed ID: 26428435
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of CXCL12-CXCR4 axis in ovarian cancer metastasis and CXCL12-CXCR4 blockade with AMD3100 suppresses tumor cell migration and invasion in vitro.
    Liu Y; Ren CC; Yang L; Xu YM; Chen YN
    J Cell Physiol; 2019 Apr; 234(4):3897-3909. PubMed ID: 30191987
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overexpression of both CXC chemokine receptor 4 and vascular endothelial growth factor proteins predicts early distant relapse in stage II-III colorectal cancer patients.
    Ottaiano A; Franco R; Aiello Talamanca A; Liguori G; Tatangelo F; Delrio P; Nasti G; Barletta E; Facchini G; Daniele B; Di Blasi A; Napolitano M; Ieranò C; Calemma R; Leonardi E; Albino V; De Angelis V; Falanga M; Boccia V; Capuozzo M; Parisi V; Botti G; Castello G; Vincenzo Iaffaioli R; Scala S
    Clin Cancer Res; 2006 May; 12(9):2795-803. PubMed ID: 16675573
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The CXCR4 antagonist AMD3100 suppresses hypoxia-mediated growth hormone production in GH3 rat pituitary adenoma cells.
    Yoshida D; Koketshu K; Nomura R; Teramoto A
    J Neurooncol; 2010 Oct; 100(1):51-64. PubMed ID: 20309720
    [TBL] [Abstract][Full Text] [Related]  

  • 10. AMD3100 reduces CXCR4-mediated survival and metastasis of osteosarcoma by inhibiting JNK and Akt, but not p38 or Erk1/2, pathways in in vitro and mouse experiments.
    Liao YX; Fu ZZ; Zhou CH; Shan LC; Wang ZY; Yin F; Zheng LP; Hua YQ; Cai ZD
    Oncol Rep; 2015 Jul; 34(1):33-42. PubMed ID: 25997540
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Insulin-Like Growth Factor 2 mRNA-Binding Protein 3 Modulates Aggressiveness of Ewing Sarcoma by Regulating the CD164-CXCR4 Axis.
    Mancarella C; Caldoni G; Ribolsi I; Parra A; Manara MC; Mercurio AM; Morrione A; Scotlandi K
    Front Oncol; 2020; 10():994. PubMed ID: 32719743
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The chemokine receptors CXCR4/CXCR7 and their primary heterodimeric ligands CXCL12 and CXCL12/high mobility group box 1 in pancreatic cancer growth and development: finding flow.
    Shakir M; Tang D; Zeh HJ; Tang SW; Anderson CJ; Bahary N; Lotze MT
    Pancreas; 2015 May; 44(4):528-34. PubMed ID: 25872129
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pro-inflammatory chemokine-chemokine receptor interactions within the Ewing sarcoma microenvironment determine CD8(+) T-lymphocyte infiltration and affect tumour progression.
    Berghuis D; Santos SJ; Baelde HJ; Taminiau AH; Egeler RM; Schilham MW; Hogendoorn PC; Lankester AC
    J Pathol; 2011 Feb; 223(3):347-57. PubMed ID: 21171080
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CXCR4 receptor blockage reduces the contribution of tumor and stromal cells to the metastatic growth in the liver.
    Benedicto A; Romayor I; Arteta B
    Oncol Rep; 2018 Apr; 39(4):2022-2030. PubMed ID: 29436696
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cancer-associated fibroblasts promote the progression of endometrial cancer via the SDF-1/CXCR4 axis.
    Teng F; Tian WY; Wang YM; Zhang YF; Guo F; Zhao J; Gao C; Xue FX
    J Hematol Oncol; 2016 Feb; 9():8. PubMed ID: 26851944
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The prognostic significance and impact of the CXCR4-CXCR7-CXCL12 axis in primary cutaneous melanoma.
    McConnell AT; Ellis R; Pathy B; Plummer R; Lovat PE; O'Boyle G
    Br J Dermatol; 2016 Dec; 175(6):1210-1220. PubMed ID: 27167239
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytotoxic drugs in combination with the CXCR4 antagonist AMD3100 as a potential treatment option for pediatric rhabdomyosarcoma.
    Regenbogen S; Stagno MJ; Schleicher S; Schilbach K; Bösmüller H; Fuchs J; Schmid E; Seitz G
    Int J Oncol; 2020 Jul; 57(1):289-300. PubMed ID: 32377699
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The CXCL12-CXCR4 Signaling Axis Plays a Key Role in Cancer Metastasis and is a Potential Target for Developing Novel Therapeutics against Metastatic Cancer.
    Yang P; Hu Y; Zhou Q
    Curr Med Chem; 2020; 27(33):5543-5561. PubMed ID: 31724498
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biological/pathological functions of the CXCL12/CXCR4/CXCR7 axes in the pathogenesis of bladder cancer.
    Nazari A; Khorramdelazad H; Hassanshahi G
    Int J Clin Oncol; 2017 Dec; 22(6):991-1000. PubMed ID: 29022185
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hypoxia stimulates CXCR4 signalling in ileal carcinoids.
    Arvidsson Y; Bergström A; Arvidsson L; Kristiansson E; Ahlman H; Nilsson O
    Endocr Relat Cancer; 2010 Jun; 17(2):303-16. PubMed ID: 20071457
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.